Beting Inhibitor for Malignant Cells

i was involved with the 11 different jackin inhibitors so far and we had a ruxolite nephidratine percretinib and now mama lotinib possibly approved. We are discovering multiple different areas of abnormalities in the malignant cells that lead us to different drugs. There were four overall presentations on npn this year anyone want presentation as a part of planarization? i'm sure there will be one approved at the end because it's active that give you a chance right.